The Name Has to Change As Growth Drives the Game

Date: May 25, 1998 Author: David P. Holveck To most people, the term biotechnology evokes the image of speculative innovation, of a research-driven, technology-based industry focused on developing novel approaches to diseases. Today, this picture is fundamentally accurate. But in the current health care environment, the biotech image is limited in scope. The term itself can create artificial boundaries between such key constituents as employees and investors, which can inhibit development and s

Written byDavid Holveck
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Date: May 25, 1998
Author: David P. Holveck

To most people, the term biotechnology evokes the image of speculative innovation, of a research-driven, technology-based industry focused on developing novel approaches to diseases. Today, this picture is fundamentally accurate. But in the current health care environment, the biotech image is limited in scope. The term itself can create artificial boundaries between such key constituents as employees and investors, which can inhibit development and stifle growth.

How companies describe themselves today is vitally important and defining. A name can be a critical factor in a company's growth process. Names shape views, convey messages, or elicit responses--good, bad, or indifferent. They can be instruments through which companies--or industries--gain focus and develop an identity that fosters growth.

Our company, Centocor, reflects this aspect of our industry's development, as we evolve from being a biotech company to a biopharmaceutical or biopharma organization. We are in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies